

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 28654

**Title:** Phase IIb trial of in vivo electroporation mediated dual-plasmid HBV DNA vaccine in chronic hepatitis B patients under lamivudine chemotherapy

**Reviewer's code:** 03538370

**Reviewer's country:** Iran

**Science editor:** Jing Yu

**Date sent for review:** 2016-07-22 18:17

**Date reviewed:** 2016-09-08 20:50

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

Dear editor Comments to authors are as follow: 1- How do you select your vaccine booster intervals? (12, 28 and ....) did you have any differences or scaling system for it? if yes, please stated in the manuscript 2- You should more discuss about CHB in introduction section, there is no information about CHB 3- "Characteristics of the patients" section should be in materials and methods not result 4- What was your eukaryotic expression vector? please state it with name in methods section 5- Why do you use this kind of linker? did you investigate it's effect on IL-2 and interferon expression? did you evaluate other kind of rigid or flexible linkers?